BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) will participate at the Immuno-Oncology 360° Conference in Boston, February 10-12, 2026. Dr. Lan Huang, Co-Founder, Chairman and CEO, will present on Plinabulin on February 11, 2026, 4:55–5:10 PM ET in the Sheraton Boston Grand Ballroom.

Presentation covers Plinabulin’s mechanism and translational strategy to enhance PD-1/PD-L1 blockade; slides will be posted afterward on the company’s Posters and Presentations webpage.

News Market Reaction – BYSI

+0.67%

1 alert

+0.67% Session close to close

$58.39M Market Cap

0.8x Rel. Volume

In the Feb 9 session, BYSI gained 0.67%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement increases Plinabulin’s scientific visibility by highlighting resistance to PD‑1/L1...

Analysis

This announcement increases Plinabulin’s scientific visibility by highlighting resistance to PD‑1/L1 therapy at a major immuno‑oncology conference. Historically, BeyondSpring has reported multiple positive DUBLIN‑3 datasets and ongoing financial losses, with mixed share reactions. Investors may focus on how these translational insights translate into registrational trial progress, regulatory strategies, and future funding steps noted in prior filings, alongside monitoring upcoming clinical milestones and any additional capital-raising activity.

Historical Context

4 past events · Latest: Dec 12 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 12	Clinical trial data	Positive	-3.2%	ESMO Asia DUBLIN‑3 Asian subset OS and neutropenia results for plinabulin combo.
Dec 11	Clinical trial data	Positive	+7.9%	Post‑hoc DUBLIN‑3 analyses showing survival benefit after anti‑PD-(L)1 therapy.
Nov 12	Earnings and update	Neutral	-3.6%	Q3 2025 results plus NSCLC cohort and SEED divestiture/milestones update.
Aug 13	Earnings and update	Positive	-0.5%	Q2 2025 financials and promising post‑PD‑1/L1 NSCLC data for Plinabulin.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and corporate news has often met with mixed or negative next-day price reactions, suggesting a history of market skepticism toward announcements.

Recent Company History

Over the past six months, BeyondSpring highlighted multiple Plinabulin datasets and financial updates. On Dec 11, 2025, strong post anti‑PD-(L)1 DUBLIN‑3 results drove a 7.92% gain, but a further positive DUBLIN‑3 subset update on Dec 12 saw a 3.21% decline. Q3 2025 earnings on Nov 12 and Q2 results on Aug 13 paired encouraging clinical data with ongoing losses, and the stock slipped 3.64% and 0.5%, respectively. Today’s conference participation fits a pattern of ongoing clinical visibility for Plinabulin.

Key Terms

immuno-oncology, PD-1/L1, biomarkers

3 terms

immuno-oncology medical

"a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

PD-1/L1 medical

"designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism"

PD-1/PD-L1 denotes a pair of proteins involved in the immune system’s “brakes” that some cancers use to hide from immune cells; drugs that target PD-1 or PD-L1 release those brakes and allow the immune system to attack tumors. Investors track PD-1/PD-L1 therapies because they represent a proven class of cancer treatments with broad clinical use, regulatory pathways, and significant revenue potential, while trial results and approvals can sharply affect a biotech’s value.

biomarkers medical

"Track Number: 1. Translational Science & Biomarkers – Expanding Therapeutic Horizons"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA.

Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical development strategy.

Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science & Biomarkers – Expanding Therapeutic Horizons
Date: Wednesday, February 11, 2026
Time: 4:55PM to 5:10PM ET
Location: Sheraton Boston Hotel, Track 1, Grand Ballroom

Following the presentation, the slides will also be available on the “Posters and Presentations” page of the Company’s website.

About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

FAQ

When will BeyondSpring (BYSI) present Plinabulin at the IO360° Conference in 2026?

BeyondSpring will present on Wednesday, February 11, 2026, from 4:55 PM to 5:10 PM ET. According to the company, Dr. Lan Huang will speak in Track 1 (Translational Science & Biomarkers) at the Sheraton Boston Grand Ballroom about Plinabulin and PD-1/PD-L1 resistance.

What topic will Dr. Lan Huang cover for BeyondSpring (BYSI) at IO360° 2026?

Dr. Lan Huang will discuss overcoming PD-1/PD-L1 resistance with Plinabulin in a translational context. According to the company, the talk will highlight Plinabulin’s unique mechanism of action and clinical development strategy aimed at enhancing PD-1/PD-L1 blockade.

Where can investors find BeyondSpring (BYSI) presentation slides after the IO360° session?

Presentation slides will be posted on the company’s Posters and Presentations page after the session. According to the company, investors can access the slides via BeyondSpring’s website following the February 11, 2026 presentation for review and reference.

How long is BeyondSpring’s (BYSI) IO360° presentation and which conference track is it on?

The presentation runs for 15 minutes, from 4:55 PM to 5:10 PM ET on February 11, 2026. According to the company, the talk is in Track 1: Translational Science & Biomarkers at the Immuno-Oncology 360° conference.

What will the BeyondSpring (BYSI) IO360° presentation imply for Plinabulin’s development timeline?

The presentation communicates translational insights and clinical strategy but does not announce new trial results or dates. According to the company, the session focuses on mechanism of action and development approach rather than specific regulatory or enrollment milestones.